Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

about

Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.

P2860

Q38442816-F0D9A7AA-5083-4A7A-88A2-12AA5DDF5805

P2860

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Item

http://www.wikidata.org/entity/Q35906506

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@ast

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@en

type

Item

label

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@ast

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@en

prefLabel

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@ast

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@en

P1476

Optimizing the Care of Patient ...... us on GLP-1 Receptor Agonists.

@en

P2093

Mansur Shomali

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Evidence based medicine: what it is and what it isn't

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Standards of medical care in diabetes--2013

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Exenatide once weekly: clinical outcomes and patient satisfaction.

P304

32-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIACLIN.32.1.32

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275821850

http://www.w3.org/2001/XMLSchema#string

P698

26246677

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4521427

http://www.w3.org/2001/XMLSchema#string

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

about

P2860

P2860

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932